SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a report that the company is preparing a formal bid to acquire eBay as part of a strategy to transform into a major e-commerce player. The community is actively debating the feasibility of the acquisition given the significant market cap discrepancy between the two companies, with many users speculating on financing methods and potential impacts on short positions.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending as investors react to preliminary quarterly results and the controversial proposal for shareholder authorization of future reverse stock splits. The community is actively divided, with many expressing frustration over persistent dilution and leadership concerns, while others highlight the potential of Tonmyas growing prescription numbers as a sign of long-term commercial momentum.

WorldFinancial

WorldFinancial (WLFI) is currently trending as investors debate its long-term viability amid a contentious governance vote on token lockups, a controversial multi-million dollar investment from UAE-affiliated partners, and ongoing allegations of a 'pump and dump' scheme. While some in the community highlight the project's potential for institutional integration and supply shocks from token burns, others are actively exiting, citing concerns over management's lack of transparency and legal scrutiny surrounding the leadership's business dealings.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

FNMA is seeing a massive surge in investor interest and social media volume, driven by prominent hedge fund managers highlighting its potential for reprivatization and massive undervaluation. The community is actively debating whether this is a genuine breakout toward a long-awaited release from government conservatorship or a classic speculative pump-and-dump scheme.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

MullenArmy participants are actively discussing the Mullen crypto token, with the community polarized between aggressive promotion of potential price runs and strong warnings from those labeling it a scam due to the history of related equity dilution. Sentiment is driven by high-risk speculation and attempts to reignite interest in the asset through community-led engagement, often drawing parallels to past volatility in the related automotive stock.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is facing significant community backlash and price volatility as investors debate its ability to compete with growth-focused rivals in a tough macroeconomic environment. Shareholders are expressing intense frustration with management's current strategy, fueling speculation that the stock remains in a precarious technical downtrend.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending as investors digest a collapsed potential acquisition by Merck, which reportedly ended negotiations due to valuation disagreements. While the immediate buyout premium has faded, community sentiment remains focused on the company's long-term potential as a leader in RAS-targeted cancer therapies.

dogwifhat (WIF) is a Solana-based memecoin featuring a Shiba Inu dog wearing a pink knitted hat that has become a central figure in the 2024-2026 market. Originally launched anonymously in late 2023, the project operates on a decentralized, community-driven model with no formal venture capital backing or complex tokenomics. It represents a cultural phenomenon on the Solana blockchain that celebrates whimsy and simplicity over technical complexity, focusing on its identity as a playful mascot for the digital finance era. The project’s main value proposition is its "Pure Meme Identity," as it maintains a strict focus on its meme origins without forced utility or a pivot toward DeFi and gaming.  The project embodies the community-driven nature of the Solana ecosystem, prioritizing "vibes" and meme-sharing as its primary growth drivers. It follows a "hat stays on" philosophy, maintaining a singular focus on its core meme rather than building a complex ecosystem. While the project does not have a formal governance structure or DAO, decisions are largely driven by social consensus among the community and key influencers. Notable community initiatives include the "Sphere Wif Hat" campaign, which raised nearly $700,000 in USDC in March 2024 to put the mascot on the Las Vegas Sphere. However, after a year of negotiations and delays, organizers officially abandoned the advertisement on March 31, 2025, and initiated a full refund process for donors.  The initial team behind dogwifhat remains anonymous, which is a standard practice within the memecoin sector. The coin's narrative is heavily influenced by prominent crypto personalities, most notably Ansem, who was a key figure in the project's early viral growth and subsequent marketing initiatives. Regarding integrations, WIF has deep liquidity across major Solana decentralized exchanges like Jupiter and Raydium, is available on the Unichain network via official contract bridging, and is listed on major centralized exchanges including Binance, Coinbase, Kraken, and Bybit.  WIF is a purely speculative asset whose value is primarily driven by community sentiment and meme culture rather than traditional utility. It was launched without a presale or significant venture capital allocation, meaning the token's supply is fully circulating. The project has achieved a "blue chip" status in the memecoin space, often serving as a beta-play for the broader health of the Solana ecosystem. No native decentralized applications or trading bots have been officially launched by the core team, as the project maintains its focus on its identity as "literally a dog wif a hat".

dogwifhat

Dogwifhat ($WIF) is facing significant community frustration as the memecoin experiences prolonged periods of stagnation and repeated sell-offs, leading many to debate whether it remains a viable investment or a declining asset. While some traders continue to advocate for patience and accumulation in anticipation of a potential altcoin breakout, others are increasingly vocal about the lack of price momentum and perceived lack of institutional interest.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing significant volatility and downward pressure as investors rotate into other sectors, despite strong fundamentals like high revenue growth and robust brand expansion. The community is actively debating the stock's disconnect from its growth narrative, with sentiment split between long-term holders accumulating at perceived support levels and bears concerned about channel inventory, commodity cost pressures, and a lack of immediate catalysts ahead of upcoming earnings.

Rayls is a Layer-1 blockchain ecosystem designed for financial institutions to bridge traditional finance (TradFi) and decentralized finance (DeFi). Developed by Parfin, Rayls combines a public chain, private networks, and institutional privacy nodes into a unified infrastructure that supports compliant, scalable, and privacy-preserving asset tokenization and settlement. Its architecture connects regulated banks and payment systems with public DeFi liquidity while maintaining confidentiality through the Rayls Enygma privacy protocol. The network enables tokenization of real-world assets, CBDCs, and stablecoins using EVM-compatible technology, fixed USD-pegged gas fees, deterministic finality, and harmful MEV protection.

Rayls

Rayls is generating significant community conversation surrounding its recent mainnet launch, which activates key tokenomics including transaction fee burns and institutional utility. While some investors are skeptical and view recent price swings as volatility, many are actively accumulating positions in anticipation of potential long-term growth and supply reduction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

<ul class="summary-bullets"><li>CMPS stock has gained 41% this week, on track for its best week ever, if gains hold.&nbsp;</li><li>The voucher, aimed at fast-tracking therapies addressing major national health priorities, entitles Compass to enhanced FDA communications and a dramatically shortened review period for COMP360.</li><li>According to data from Koyfin, 11 of the 12 analysts covering CMPS rate it ‘Buy’ or higher, while one rates it ‘Hold.’</li></ul>Shares of Compass Pathways (CMPS ) climbed 5.5% on Friday, adding to a larger rally this week, after the company said that the U.S. Food and Drug Administration granted its synthetic psilocybin formulation the Commissioner's National Priority Voucher for treatment-resistant depression.CMPS stock has gained 45% this week, on track for its best week ever, if gains hold.The voucher, aimed at fast-tracking therapies addressing major national health priorities, entitles Compass to enhanced FDA communications and a dramatically shortened review period for COMP360, as little as 1-2 months after the application is filed.The company said that the agency has granted its rolling application request, allowing it to submit completed sections of its application rather than waiting for every section to be completed before review commences.Compass has conducted two late-stage studies for COMP360, generating data across more than 1000 patients with treatment-resistant depression. COMP360 may demonstrate effects as quickly as within one day after administration, with durability lasting at least through 6 months for those who achieve a clinically meaningful response after one or two doses, Compass said.<h2 class="st-heading-2">Trump’s Push For Psychedelics</h2>President Trump, over the last weekend, signed an executive order directing health agencies to speed up research on drugs like psilocybin and ibogaine.Earlier on Friday, the FDA also stated it will issue national priority vouchers to three companies studying psilocybin for the treatment of treatment-resistant depression and major depressive disorder, and methylone for the treatment of PTSD. However, Compass is the only publicly traded company in the U.S. among the three.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CMPS stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user expressed optimism for a further rally to $11.<stembedurl>https://www.stocktwits.com/texmade2/message/651311854</stembedurl>Another user opined that the market reaction to the priority review voucher announcement “feels too muted.”<stembedurl>https://www.stocktwits.com/ChristopherMcC/message/651309288</stembedurl>A third user termed the stock “super undervalued.”<stembedurl>https://www.stocktwits.com/Millionaire11/message/651299529</stembedurl>According to data from Koyfin, 11 of the 12 analysts covering CMPS rate it ‘Buy’ or higher, while one rates it ‘Hold.’ The stock has a 12-month average price target of $22.08, implying a potential upside of about 141% from the last closing price.On Friday, B. Riley initiated coverage of Compass Pathways with a ‘Buy’ rating and $17 price target. The company is on track to develop the first FDA-approved oral psychedelic drug for treatment-resistant depression, but the stock trades in the bottom percentile of its psychedelic peers, the analyst told investors in a research note.&nbsp;<a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> has gained 142% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-lidr-stock-surging-today/cZBh9Q3Rec0">LIDR Stock Surges 35% – This Analyst Sees Potential Returns Of 4-5x Over Time</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CMPS On Track For Best Week Ever On FDA Push For Psychedelics

Compass said on Friday that the FDA has granted its synthetic psilocybin formulation the Commissioner's National Priority Voucher for treatment-resistant depression.

Equity

Compass said on Friday that the FDA has granted its synthetic psilocybin formulation the Commissioner's National Priority Voucher for treatment-resistant depression.


<ul class="summary-bullets"><li>The trial results were presented in a late-breaking oral session at the American Academy of Neurology (AAN) Annual Meeting in Chicago.</li><li>At 16 weeks, mobility improved significantly with eighty-one percent of patients achieving a clinically meaningful improvement, the company said.&nbsp;</li><li>Kyverna said the data support its plan to submit a biologics license application (BLA) to the FDA for miv-cel in SPS.</li></ul>Shares of Kyverna Therapeutics, Inc. (KYTX) jumped 24% after hours on Tuesday after the company said that its experimental one-time CAR-T cell therapy delivered rapid, lasting improvements in mobility and reversed disability in patients with stiff person syndrome (SPS) in a trial.The results were presented in a late-breaking oral session at the American Academy of Neurology (AAN) Annual Meeting in Chicago.<h2 class="st-heading-2">Trial Results</h2>In the phase-2 trial, 26 patients who had not responded well to standard off-label therapies received a single dose of Kyverna’s miv-cel.At 16 weeks, mobility improved significantly; eighty-one percent of patients achieved a clinically meaningful improvement. Two-thirds of those who needed walking aids at the start no longer required them. All 26 patients were able to stop chronic immunotherapies entirely, the company said. Disability, muscle stiffness, and sensitivity to spasms also improved markedly, it added.Miv-cel was generally well-tolerated. The most common side effect was a temporary drop in neutrophil cell counts that was manageable, Kyverna said.<h2 class="st-heading-2">What Next?</h2>Kyverna said the data support its plan to submit a biologics license application (BLA) to the FDA for miv-cel in SPS. If approved, it would become the first approved treatment for the condition and the first CAR-T therapy approved for any autoimmune disease.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around KYTX stayed within the ‘extremely bullish’ territory over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed optimism for the company, highlighting the past experiences of its CEO Warner Biddle who previously worked with Kite Pharma. Kite was bought out by Gilead Sciences for $11.9 billion in 2017.<stembedurl>https://www.stocktwits.com/beststock/message/650960443</stembedurl>Another opined that miv-cel has a total addressable market of over $80 billion if its approved across multiple indications.<stembedurl>https://www.stocktwits.com/leon_dedrick/message/650960360</stembedurl><a href="https://stocktwits.com/symbol/KYTX">KYTX stock</a> has gained 11% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nio-gives-its-model-nemesis-lidar-vision-wallet-friendly-price-tag-unchanged/cZBIxJ6RI6N">NIO Gives Its Model Y Nemesis LiDAR Vision — Wallet-Friendly Price Tag Unchanged</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

KYTX Stock Soars After Hours: What’s Driving The Rally? 

Kyverna reported strong pivotal trial results for its one-time CAR-T therapy miv-cel, showing rapid mobility improvements and reversal of disability in patients with stiff person syndrome.

Should You Invest in the iShares Biotechnology ETF (IBB)?

<ul class="summary-bullets"><li>Legend, like Kelonia, develops and manufactures cell therapies to treat life-threatening diseases, particularly cancer.</li><li>Legend is best known for Carvykti, a CAR-T treatment for relapsed or refractory multiple myeloma, developed and marketed in collaboration with Johnson &amp; Johnson.</li></ul>Shares of Legend Biotech (LEGN) closed 18% higher on Monday, its best day since April 2023, following Eli Lilly and Company’s (LLY) buyout of its rival Kelonia Therapeutics for up to $7 billion.Lilly said earlier in the day that it has entered into a definitive agreement to acquire Kelonia to advance CAR-T cell therapies. Kelonia's lead program, KLN-1010, is an in vivo CAR-T therapy currently in early-stage studies for relapsed/refractory multiple myeloma.Under the terms of the deal, Lilly will pay Ketonia shareholders an upfront payment of $3.25 billion in addition to milestone payments. The transaction is expected to close in the second half of 2026.Legend, like Kelonia, develops and manufactures cell therapies to treat life-threatening diseases, particularly cancer. It is best known for Carvykti, a CAR-T treatment for relapsed or refractory multiple myeloma, developed in collaboration with Johnson &amp; Johnson (JNJ).Last month, Legend said that more than 10,000 patients have been treated with Carvykti and that the franchise achieved profitability for the full year 2025. Carvykti net trade sales came in at $1.9 billion for the year.<h2 class="st-heading-2">Wall Street Takeaway</h2>Following the deal announcement, RBC Capital reportedly reiterated an ‘Outperform’ rating and $62.00 price target on Legend Biotech, opining that it highlights large pharma interest in the CAR-T market, according to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://m.in.investing.com/news/stock-market-news/rbc-capital-reiterates-legend-biotech-stock-rating-on-pharma-interest-93CH-5346810?ampMode=1">report</a> from Investing.com. Legend has potential sales of $2.8 billion in 2026, according to RBC.H.C. Wainwright also reiterated a ‘Buy’ rating with a $50 price target citing progress across the company’s CAR-T therapy programs, as <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://in.investing.com/news/stock-market-news/hc-wainwright-reiterates-legend-biotech-stock-rating-on-pipeline-progress-93CH-5345904">per</a> Investing. First-in-human data from the LUCAR-G39D in vivo cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma is expected to start rolling in during the second half of 2026, with Wainwright flagging ASCO 2026 conference in late May to in early June as a plausible venue for the first readout.According to data from Koyfin, 14 of 16 analysts covering LEGN rate it ‘Buy’ or higher while two rate it ‘Hold.’ The 12-month average price target on the stock is $57.23, presenting a potential upside of about 128% from last close.<h2 class="st-heading-2"> How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around LEGN stayed within the ‘extremely bullish’ territory while message volume jumped from ‘high’ to ‘extremely high’ levels.A Stocktwits user sounded optimistic for Johnson &amp; Johnson acquiring Legend to “not split the revenue” with Carvykti.<stembedurl>https://www.stocktwits.com/Realtrader77/message/650805222</stembedurl>Another voiced optimism for the company getting bought out for $41/ per share, presenting significant upside.<stembedurl>https://www.stocktwits.com/Stockseeking/message/650804814</stembedurl><a href="https://stocktwits.com/symbol/LEGN">LEGN stock</a> has fallen 22% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/jetblue-ceo-vows-strong-cash-pile-will-prevent-bankruptcy-in-2026-report/cZBdZIgRIzp">JetBlue CEO Vows Cash Pile Will Prevent Bankruptcy in 2026: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Legend Biotech Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

LEGN Stock Clocks Best Day In Three Years — What’s Driving The Rally?

After Eli Lilly and Company bought Kelonia to advance CAR-T cell therapies, retail traders are now speculating a buyout for Legend. 

<ul class="summary-bullets"><li>Anavex stated it withdrew the application for blarcamesine after the EMA’s Committee for Medicinal Products for Human Use indicated that it would not issue a positive opinion for the company’s Alzheimer’s drug at this time.</li><li>The company added that it filed the blarcamesine application following guidance from the EMA’s small and medium-sized enterprises office to move forward with marketing authorization preparations.</li><li>This comes two days after Anavex reported new data about blarcamesine, suggesting a slowdown in brain shrinkage.</li></ul>Anavex Life Sciences Corp. (AVXL) shares tanked more than 33% in Wednesday’s opening trade after the company announced that it has withdrawn its marketing authorization application for its Alzheimer’s drug, blarcamesine, in the European Union.Anavex stated that the decision to withdraw the application follows feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.This comes two days after Anavex&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/avxl-stock-soars-anavex-alzheimers-drug-blarcamesine-slows-brain-shrinkage/cZ3mhyrRI0F">reported</a> new data about blarcamesine, suggesting a slowdown in brain shrinkage.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AVXL">Anavex Life Sciences</a> trended in the ‘extremely bullish’ territory at the time of writing.<h2 class="st-heading-2">Why Did Anavex Withdraw Application?</h2>Anavex stated that it withdrew the application for blarcamesine after the EMA’s Committee for Medicinal Products for Human Use indicated that it would not issue a positive opinion for the company’s Alzheimer’s drug at this time.The company added that it filed the blarcamesine application following guidance from the EMA’s small and medium-sized enterprises (SMEs) office to move forward with marketing authorization preparations.“Anavex now has to take note of the differing assessment of the CHMP at the EMA and will consider the constructive feedback received from the CHMP and focus on gathering additional data and conducting further analyses to address the points raised by the CHMP,” the company stated.<h2 class="st-heading-2">New Blarcamesine Trial Data Suggests Slowdown In Brain Shrinkage</h2>Earlier this week, Anavex reported new data about blarcamesine, suggesting a slowdown in brain shrinkage. Brain shrinkage is a key marker of Alzheimer’s progression.At the AD/PD 2026 Conference, Anavex presented new data on blarcamesine from its Phase IIb and Phase III programs, indicating that preservation of brain volume is associated with improved patient outcomes.The company said its trial data suggest patients with wild-type SIGMAR1 and COL24A1 genes may see greater clinical and structural benefits from blarcamesine.MRI biomarker analysis showed a strong and consistent link between reduced brain atrophy and improvements in cognition, daily activities, and overall clinical outcomes, Anavex said.<a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> is down 21% year-to-date and 71% over the past 12 months. The SPDR S&amp;P Biotech ETF (XBI) is up 43% over the past 12 months, while the iShares Biotechnology ETF (IBB) is up 25%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lmt-stock-lockheed-martin-quadruple-precision-strike-missiles-production-iran-war/cZ3YFRyRIS9">Lockheed Martin To Quadruple Precision Strike Missile Output After First Combat Use In Iran War</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, an Anavex Life Sciences Corp. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug

Anavex stated that the decision to withdraw the application follows feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

<ul class="summary-bullets"><li>The company said that its trial data also show that patients with wild-type SIGMAR1 and COL24A1 genes may experience substantially greater clinical and structural benefit from blarcamesine.</li><li>An analysis of MRI biomarkers showed a strong and consistent correlation between reduced brain atrophy and improvements across primary and secondary clinical endpoints, Anavex said.</li><li>This includes cognition, activities of daily life, and global clinical cognitive and functional outcome.</li></ul>Anavex Life Sciences Corp. (AVXL) on Monday reported new data about its Alzheimer’s drug blarcamesine, suggesting a slowdown in brain shrinkage.At the AD/PD 2026 Conference, Anavex presented new data on blarcamesine from its Phase IIb and Phase III program, indicating that preservation of brain volume is linked to improved patient outcomes. The drug remains investigational and has not been approved by regulators.<a href="https://stocktwits.com/symbol/AVXL">Anavex shares</a> were up more than 13% in Monday’s opening trade.<h2 class="st-heading-2">What Does The Data Show?</h2>Anavex stated that the new data points to a reduction in brain volume loss over time. Brain shrinkage is a key marker of Alzheimer’s progression.“The patient-friendly oral administration, the manageable side effects, and the clinical efficacy—particularly in the genetically defined ABCLEAR3 population—make blarcamesine, in conjunction with the associated biomarker signal, a promising drug candidate for patients with early-stage Alzheimer’s disease,” said Timo Grimmer, member of the Anavex Scientific Advisory Board.The company said that its trial data also shows that patients with wild-type SIGMAR1 and COL24A1 genes may experience substantially greater clinical and structural benefit from blarcamesine.An analysis of MRI biomarkers showed a strong and consistent correlation between reduced brain atrophy and improvements across primary and secondary clinical endpoints, including cognition, activities of daily life, and global clinical cognitive and functional outcome.“The consistent relation between structural preservation of brain volume and functional outcomes further drives our dedication to developing a novel disease-modifying Alzheimer’s treatment with our oral blarcamesine,” said Anavex CEO Christopher U. Missling.<h2 class="st-heading-2">What Does Anavex Do?</h2>Anavex is a New York-based biopharmaceutical that is involved in the development of therapeutics for the treatment of various disorders, including Alzheimer’s disease, Parkinson’s disease, and schizophrenia, among others.The company’s preclinical studies of blarcamesine showed that the oral drug candidate has the potential to halt or reverse the course of Alzheimer’s disease.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory, with message volumes at ‘high’ levels at the time of writing.One bullish user said that Anavex’s brain volume preservation data is “incredibly exciting.”<stembedurl>https://stocktwits.com/Logic102/message/648270407</stembedurl><a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> is up 26% year-to-date, but down 54% over the past 12 months. The SPDR S&amp;P Biotech ETF (XBI) is up 41% over the past 12 months, while the iShares Biotechnology ETF (IBB) is up 23%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gold-price-recovers-as-trump-postpones-attack-on-iran-5-days-down-16-month/cZ3ma5TRI0O">Gold Price Recovers To $4,450 On Trump’s Iran Attack Pause – But Yellow Metal Is Still Down 15% In A Month After ‘Sell Everything’ Rout</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AVXL Stock Soars After Anavex’s New Data Suggests Its Alzheimer’s Drug May Slow Brain Shrinkage

Anavex presented new data from its Phase IIb and Phase III blarcamesine programs, showing that preservation of brain volume is associated with improved patient outcomes.

The Zacks Analyst Blog Highlights IBB, XBI, BBH and GNOM

IBB and peers are gaining traction as AI transforms biotech, boosting drug discovery, trials and growth prospects across diversified ETF portfolios.

Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave

IBB and other biotech ETFs are gaining traction as AI reshapes drug discovery, genomics, and clinical trials, giving investors diversified exposure to biotech innovation.

<ul><li>H.C. Wainwright stated that it “reshapes the regulatory calculus” for the company’s Huntington’s disease gene therapy, AMT-130.</li><li>The firm stated that it has “continued conviction” in AMT-130's existing dataset and uniQure's broader pipeline.</li><li>Analysts at Chardan nearly doubled their price target for uniQure to $31 from $16, while keeping a ‘Buy’ rating, citing Prasad’s departure for its optimism.</li></ul>uniQure NV stock continued to draw retail buzz after analysts at H.C. Wainwright noted on Tuesday that the shares are poised for a value inflection following the reported departure of a key U.S. Food and Drug Administration (FDA) official.According to TheFly, analysts at H.C. Wainwright reiterated their ‘Buy’ rating and a $70 price target for the stock, implying a potential upside of nearly 289% from Monday’s closing price.<a href="https://stocktwits.com/symbol/QURE">uniQure shares</a> were up nearly 7% in Tuesday’s pre-market trade after a 26% surge on Monday.<h2 class="st-heading-2">Why Is HC Wainwright Bullish?</h2>H.C. Wainwright stated that the departure of Vinay Prasad, the head of the FDA’s division of vaccines and gene therapies at the end of April, bodes well for uniQure, stating that it “reshapes the regulatory calculus” for the company’s Huntington’s disease gene therapy, AMT-130.H.C. Wainwright stated that it has “continued conviction” in AMT-130's existing dataset and uniQure's broader pipeline.Prasad is reportedly leaving the agency next month to return to academia.Analysts at Chardan nearly doubled their price target for uniQure to $31 from $16, while keeping a ‘Buy’ rating. The firm cited Prasad’s departure as the reason for its price target hike.Earlier this month, the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-qure-stock-almost-halve-pre-market-today/cZd344CRIcD">FDA&nbsp;</a>said it does not agree that uniQure’s Phase I/II data for AMT-130 are sufficient to serve as theprimary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy.“While we did not reach alignment on a submission pathway based on the Phase I/II data, we believe the totality and durability of our data warrant continued substantive dialogue regarding how the FDA’s stated commitment to regulatory flexibility may be appropriately applied in this setting,” said uniQure CEO Matt Kapusta.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around uniQure trended in the ‘bullish’ territory at the time of writing.One user stated that this is the “gene therapy trade reset traders waited for.”<stembedurl>https://stocktwits.com/TradeThePool/message/647080386</stembedurl><a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is down 25% year-to-date, but up 45% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bill-ackman-pershing-square-files-for-ipo-after-a-delay-of-more-than-a-year/cZdoYmJRIeU">Bill Ackman’s Pershing Square Files For IPO After A Delay Of More Than A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure

H.C. Wainwright stated that the reported departure of a key U.S. Food and Drug Administration official at the end of April bodes well for uniQure.

IBB
iShares Biotechnology ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IBB News

IBBiShares Biotechnology ETF